ZOLL® Medical Corporation announced that the peer-reviewed journal Nature and Science of Sleep has published five-year results from the remedē System Post Approval Study. The data show sustained safety and efficacy of transvenous phrenic nerve stimulation for the treatment of moderate to severe central sleep apnea (CSA). The remedē® System, the only implantable device […]
Sleep Apnea
First Patient Dosed in Second Phase 2 Clinical Trial of Oral OSA Medication
Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating AD109 as a treatment for mild to moderate OSA. If successful, AD109 could offer an […]
Older Undiagnosed OSA Patients Need More Medical Care
Older adults with undiagnosed obstructive sleep apnea seek more health care, according to a study published in the January issue of the Journal of Clinical Sleep Medicine. The study examined the impact of untreated sleep apnea on health care utilization and costs among Medicare beneficiaries. The authors reviewed a sample of Medicare […]
Don’t Look Back: New Treatments for Positional OSA
By Matthew Anastasi, BS, RST, RPSGT Located in the tiny village of Merida, Venezuela is Heladería Coromoto, an ice cream parlor, known for offering a Guinness Record for most flavors of ice cream in the world (860 varieties). Despite our sometimes homogeneous view of the condition, sleep-disordered breathing (SDB) has […]
Trucking Firm Sees Big Insurance Savings with OSA Treatment
A research team led by the University of Minnesota Morris found that a trucking firm that mandated treatment for its drivers with obstructive sleep apnea (OSA) saved significantly on non-OSA-program medical insurance costs. Despite evidence that untreated OSA is associated with significantly higher rates of serious preventable truck crashes, the U.S. Department […]
Obituary: Dr. Christian Guilleminault, Sleep Medicine Pioneer
It is with the utmost respect that we announce the passing of Dr. Christian Guilleminault July 9, 2019, in Palo Alto, CA, from metastatic cancer. Guilleminault was surrounded by family, colleagues, and fellows during his final days. The messages and outreach from across the globe have been overwhelming this past […]
New Study Investigates the Use of Home Monitoring to Screen Children with Down Syndrome for Risk of OSA Prior to Multichannel Sleep Studies
Masimo has announced the findings of a recently published study in which researchers investigated whether home pulse oximetry monitoring might be a useful initial screening method of determining which children with Down syndrome (DS) – who are at high risk of obstructive sleep apnea (OSA) – be recommended to undergo […]
Clinical Trial for Treating OSA Using Cannabinoid-based Drug
Therapix Biosciences Ltd., a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced that on June 05, 2018, the first subject was enrolled for its Phase IIa, sponsor-initiated clinical trial using the Company’s cannabinoid-based technology THX-110 for Obstructive Sleep Apnea (OSA), at Assuta Medical Center, the largest […]
Nearly 1 Billion People Worldwide Have Sleep Apnea
Researchers analyzed prevalence studies from 16 countries, together with data from the World Health Organization and United Nations World Population Prospects A new data analysis presented by ResMed this week at the ATS 2018 International Conference indicates that the prevalence of sleep apnea impacts more than 936 million people worldwide […]
Philips Continues to Change the Face of Sleep Apnea with Latest Addition to the DreamWear Family
New full face mask brings the benefits of DreamWear CPAP mask system to broader patient population with more freedom of choice and increased flexibility Today at Medtrade Spring in Las Vegas, Nevada (March 27-29), Royal Philips, announced the launch of DreamWear Full face, the third mask option available for its […]













